CMIC is the largest CRO in Japan, working in Queensland Australia for conducting early to late phase clinical trials. CMIC provides end-to-end solutions from clinical development to commercialization in Japan and Asian markets.
CMIC is the first and largest CRO in Japan with 1,200+ Clinical Research Associates (CRAs) including Asia-Pacific. We have multinational clinical study trial management expertise, and our clinical operations services are available in Japan, APAC, Australia and New Zealand. CMIC Group also offers Contract Development and Manufacturing Organization (CDMO) service for drug manufacturing and packaging, Contract Sales Organization (CSO) to provides various services/solutions for sales and marketing activities, Innovative Pharma Model (IPM) with full pharmaceutical capabilities for overseas business partners to enter into Japan market, as well as Patient and Healthcare Services to provides patient-centered healthcare solutions.
CMIC group has been inspected and passed inspections from several international regulatory authorities: US FDA, Japan PMDA, Korea MFDS, Taiwan FDA and Singapore HSA.
Therapeutic areas include: Cardiovascular Diseases, Congenital, Hereditary and Neonatal Diseases and Abnormalities, Digestive System Diseases, Endocrine System Diseases, Eye Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Immune System Diseases, Male Urogenital Diseases, Mental Disorders, Musculoskeletal Diseases, Neoplasms, Nervous System Diseases, Nutritional and Metabolic Diseases, Otorhinolaryngologic Diseases, Respiratory Tract Diseases, Skin and Connective Tissue Diseases.